Alacris Theranostics GmbH is a Berlin-based company specialising in the development of new approaches for personalised medicine for cancer patient diagnosis, treatment and drug stratification.
Alacris Theranostics applies a systems biology approach, designated ModCellTM, that was originally developed at the Max Planck Institute for Molecular Genetics by Prof. Lehrach’s research team and is exclusively licensed to Alacris Theranostics. Based on next-generation sequencing-derived genome and transcriptome information, kinetic pathway information, and mutation and drug databases, ModCellTM provides a ‘Virtual Patient’ model… read more
Berlin, 1st April 2014 – Alacris Theranostics has entered into a project with SAP AG (NYSE: SAP) to use the
Alacris Theranostics became a member of an international research project to analyse the genetic and molecular causes of bone diseases,
Alacris Theranostics GmbH announced today that it has successfully completed Illumina CSPro™ certification for next generation sequencing (NGS); gaining entry
Berlin, 14th November 2012 – Alacris Theranostics has entered into an agreement with GlaxoSmithKline (GSK) to apply Alacris’ proprietary ModCellTM
German business journal “Wirtschaftswoche” considers the continuous upward trend of biotech start-ups in Germany, especially Alacris Theranostics as one of